Previous Close | 15.60 |
Open | 15.60 |
Bid | 17.69 x 900 |
Ask | 17.74 x 1200 |
Day's Range | 15.50 - 18.04 |
52 Week Range | 7.67 - 47.90 |
Volume | |
Avg. Volume | 481,121 |
Market Cap | 701.305M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.44 |
Earnings Date | Aug 02, 2022 - Aug 08, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 47.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for INBX
Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a robust preclinical pipeline, today announced the completion of Phase 1 dose escalation of INBRX-105, a novel targeted 4-1BB agonist, in combination with Keytruda®. It also reported the funding of an additional $60 million from its Loan and Security Agreement, as amended (the "Loan Agreement"), with Oxford Finance, LLC ("Oxford"), to bring its cash balance to approximately $176 million as of Jun
Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced today that it will be presenting details on the trial design for the INBRX-109 Phase 2 potentially registration-enabling trial in conventional chondrosarcoma at the 2022 American Society of Clinical Oncology ("ASCO") Annual Meeting to be held June 3rd through June 7th, 2022 in Chicago, Illinois.
Inhibrx Inc (NASDAQ: INBX) announced topline results from a Phase 1 clinical trial of INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with alpha-1 antitrypsin deficiency (AATD). AATD is an inherited condition that raises lung and liver disease risks. AAT is a protein that protects the lungs, and the liver makes it. Treatment was well tolerated, with no severe or serious adverse events related to the study drug. Related: Inhibrx Shares Interim Data On INBRX-106 - Keyt